Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

NCT03236844 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche